Oncology Institute (NASDAQ:TOI) Now Covered by Analysts at Lake Street Capital

Posted by Brian Himes on Jul 7th, 2026

Lake Street Capital started coverage on shares of Oncology Institute (NASDAQ:TOI – Free Report) in a research note issued to investors on Monday morning, Marketbeat reports. The firm issued a buy rating and a $10.00 price target on the stock.

TOI has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Monday, April 20th. Needham & Company LLC lifted their price target on Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. B. Riley Financial upped their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, BTIG Research lifted their price objective on shares of Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Oncology Institute has a consensus rating of “Moderate Buy” and an average price target of $8.20.

Read Our Latest Research Report on Oncology Institute

Oncology Institute Price Performance

Shares of NASDAQ TOI traded up $0.05 during trading hours on Monday, reaching $5.49. The stock had a trading volume of 95,550 shares, compared to its average volume of 1,886,106. The business’s fifty day moving average is $4.62 and its two-hundred day moving average is $3.68. Oncology Institute has a twelve month low of $2.32 and a twelve month high of $5.82. The company has a market cap of $542.43 million, a price-to-earnings ratio of -14.80 and a beta of 0.36.

Oncology Institute (NASDAQ:TOI – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million during the quarter, compared to the consensus estimate of $142.10 million. Sell-side analysts forecast that Oncology Institute will post -0.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Oncology Institute

In other news, insider Yale Podnos sold 23,451 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider directly owned 259,527 shares in the company, valued at $1,396,255.26. The trade was a 8.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 33,500 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $4.07 per share, for a total transaction of $136,345.00. Following the acquisition, the insider owned 10,567,858 shares of the company’s stock, valued at approximately $43,011,182.06. This trade represents a 0.32% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 118,500 shares of company stock valued at $488,655 and sold 119,170 shares valued at $461,183. Insiders own 4.40% of the company’s stock.

Institutional Trading of Oncology Institute

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new position in shares of Oncology Institute in the first quarter worth approximately $131,000. Geode Capital Management LLC grew its stake in Oncology Institute by 231.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock worth $2,623,000 after buying an additional 893,696 shares in the last quarter. Cetera Investment Advisers increased its holdings in shares of Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after buying an additional 4,545 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Oncology Institute by 51,631.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 27,935 shares of the company’s stock valued at $57,000 after buying an additional 27,881 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Oncology Institute during the 2nd quarter worth $92,000. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

(Get Free Report)

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.